Background and Aims: Lipoprotein(a) is causally associated with the risk of CVD. Novel therapies that potently and specifically reduce plasma concentration of lipoprotein(a) by up to 70−80% are currently in development. We sought to examine whether the effect of lipoprotein(a) lowering on risk of CVD is modified by LDL cholesterol (LDL-C) level, gender, and antiplatelet therapy to inform the design of clinical outcome trials.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Published online: August 03, 2019EAS19-0777
© 2019 Published by Elsevier Inc.